Abstract
Biotechnology Law ReportVol. 35, No. 4 The Holman ReportThe Medicines Company v. Hospira: When Does Outsourcing Drug Manufacture to a Third-Party Contractor Trigger an On-Sale Bar to Patentability?Christopher M. HolmanChristopher M. HolmanSearch for more papers by this authorPublished Online:1 Aug 2016https://doi.org/10.1089/blr.2016.29023.cmhAboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 35Issue 4Aug 2016 InformationCopyright 2016, Mary Ann Liebert, Inc.To cite this article:Christopher M. Holman.The Medicines Company v. Hospira: When Does Outsourcing Drug Manufacture to a Third-Party Contractor Trigger an On-Sale Bar to Patentability?.Biotechnology Law Report.Aug 2016.129-136.http://doi.org/10.1089/blr.2016.29023.cmhPublished in Volume: 35 Issue 4: August 1, 2016PDF download
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
